IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Safety

Safety desk

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

Safety is the first clinical topic, not the last paragraph. Ibogaine coverage has to foreground QT/QTc, rhythm risk, medication interactions, exclusions, adverse events, and emergency readiness before benefit language.

Ibogaine is associated with serious cardiac and interaction risks. Research settings and medical discussions emphasize screening, monitoring, exclusion criteria, medication review, and emergency response capacity.

QT/QTc and rhythm
Plain-English explanation of QT interval, QTc correction, bradycardia, arrhythmia concern, electrolyte context, and why published studies keep returning to the heart.
Medication interactions
Conceptual map of drug classes that raise concern, including opioids, stimulants, alcohol, benzodiazepines, serotonergic drugs, QT-prolonging drugs, and CYP2D6 issues.
Adverse events
Deaths, case reports, emergency transfers, and uncertain causality are tracked without sensationalizing or minimizing them.